Immunocore Reports Strong Revenue Growth and Reduced Losses in 2025, Advances Deep Pipeline
IMCR sits 43% above its 52-week low of $23.15.
Summary
Immunocore Holdings plc reported strong 29% revenue growth and a reduced net loss in its 2025 annual report, driven by KIMMTRAK sales and continued significant investment in its diverse clinical pipeline.
Key Events · Earnings and Guidance · IMCR
-
Strong Revenue Growth
Net revenue from the sale of therapies increased by 29% to $400.0 million for the year ended December 31, 2025, up from $310.0 million in 2024, primarily due to increased volume in the United States and Europe for KIMMTRAK.
-
Reduced Net Loss
The company significantly reduced its net loss to $35.5 million in 2025, an improvement from a net loss of $51.1 million in 2024, indicating progress towards profitability.
-
Healthy Liquidity Position
Immunocore reported cash and cash equivalents of $467.7 million and marketable securities of $396.4 million as of December 31, 2025, providing sufficient funds for at least 12 months of operations.
-
Advancing Clinical Pipeline
R&D expenses increased by 24% to $274.9 million, reflecting continued investment in advancing multiple programs, including Phase 3 trials for KIMMTRAK and brenetafusp, and new autoimmune candidates (IMC-S118AI, IMC-U120AI) entering or planning clinical trials.
Analysis · IMCR · Life Sciences
Immunocore Holdings plc's annual 10-K filing for fiscal year 2025 reveals robust financial performance driven by its lead product, KIMMTRAK. The company achieved a significant 29% increase in net revenue from therapy sales, reaching $400.0 million, and successfully narrowed its net loss to $35.5 million from $51.1 million in the prior year. This financial improvement is supported by a healthy cash and marketable securities balance of $864.1 million, providing over 12 months of liquidity. The company continues to heavily invest in its pipeline, with R&D expenses increasing by 24% to $274.9 million, reflecting progress in multiple clinical trials for oncology, infectious diseases, and new autoimmune candidates. While the resignations of the Head of R&D and CHRO are noted, and a deferred tax expense was recognized, the overall operational and financial advancements signal positive momentum for the company's growth trajectory.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCR was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $23.15 to $40.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.